EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)VergleichsstudieMultizentrische StudieOpen Access

Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA

Mazyar Shadman iD, Talha Munir, Tadeusz Robak iD, Jennifer R Brown iD, Brad S Kahl iD, Paolo Ghia iD, Krzysztof Giannopoulos iD, Martin Šimkovič iD, Anders Österborg, Luca Laurenti, Patricia A Walker, Stephen S Opat iD und 21 weitere

Journal of Clinical Oncology · 2025-03 · 43 (7) · 780-787

DOI: 10.1200/jco-24-02265 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2025-03. Verfasst von Mazyar Shadman und 32 weiteren Autor:innen. Beteiligte Einrichtung: Fred Hutchinson Cancer Center, University of Washington, Seattle, WA. Hauptthemen laut MEDLINE: Bendamustine Hydrochloride, Leukemia, Lymphocytic, Chronic, B-Cell, Antineoplastic Combined Chemotherapy Protocols, Pyrimidines. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. SEQUOIA (ClinicalTrials.gov identifier: NCT03336333 ) is a phase III, randomized, open-label trial that compared the oral Bruton tyrosine kinase inhibitor zanubrutinib to bendamustine plus rituximab (BR) in treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The initial prespecified analysis (median follow-up, 26.2 months) and subsequent analysis (43.7 months) found superior progression-free survival (PFS; the primary end point) in patients who received zanubrutinib compared with BR. At a median follow-up of 61.2 months, median PFS was not reached in zanubrutinib-treated patients; median PFS was 44.1 months in BR-treated patients (hazard ratio [HR], 0.29; one-sided P = .0001). Prolonged PFS was seen with zanubrutinib versus BR in patients with mutated immunoglobulin heavy-chain variable region (IGHV) genes (HR, 0.40; one-sided P = .0003) and unmutated IGHV genes (HR, 0.21 [95% CI, 0.14 to 0.33]; one-sided P < .0001). Median overall survival (OS) was not reached in either treatment arm; estimated 60-month OS rates were 85.8% and 85.0% in zanubrutinib- and BR-treated patients, respectively. No new safety signals were detected. Adverse events were as expected with zanubrutinib; rate of atrial fibrillation was 7.1%. At a median follow-up of 61.2 months, the results supported the initial SEQUOIA findings and suggested that zanubrutinib was a favorable treatment option for untreated patients with CLL/SLL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bendamustine HydrochlorideLeukemia, Lymphocytic, Chronic, B-CellAntineoplastic Combined Chemotherapy ProtocolsPyrimidinesRituximabPyrazolesPiperidinesHumansFemaleMaleMiddle AgedAgedFollow-Up StudiesAdultAged, 80 and overProgression-Free Survival

Substanzen

Bendamustine HydrochloridezanubrutinibPyrimidinesRituximabPyrazolesPiperidines

Autor:innen und Institutionen

  • Fred Hutchinson Cancer Center, University of Washington, Seattle, WA.
  • Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.
  • Copernicus Memorial Hospital, Medical University of Łódź, Łódź, Poland.
  • Dana-Farber Cancer Institute, Boston, MA.
  • Siteman Cancer Center, Washington University School of Medicine, St Louis, MO.
  • Università Vita-Salute San Raffaele, Milano, Italy.

ORCID-Profile: Mazyar Shadman, Tadeusz Robak, Jennifer R Brown, Brad S Kahl, Paolo Ghia, Krzysztof Giannopoulos, Martin Šimkovič, Stephen S Opat, Richard Greil, Marek Trněný, Danielle Brander, Ian W Flinn, Emma Verner, Kamel Laribi, Andy Szeto, Constantine S Tam

Zitieren

APA

Shadman, M., Munir, T., Robak, T., Brown, J. R., Kahl, B. S., Ghia, P., Giannopoulos, K., Šimkovič, M., Österborg, A., Laurenti, L., Walker, P. A., Opat, S. S., Ciepluch, H., Greil, R., Hanna, M., Tani, M., Trněný, M., Brander, D., Flinn, I. W., …, & Jurczak, W. (2025). Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA. Journal of Clinical Oncology, 43(7), 780-787. https://doi.org/10.1200/jco-24-02265

Vancouver

Shadman M, Munir T, Robak T, Brown JR, Kahl BS, Ghia P, et al. Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA. Journal of Clinical Oncology. 2025;43(7):780-787. doi:10.1200/jco-24-02265

BibTeX
@article{Shadman2025,
  author = {Shadman, Mazyar and Munir, Talha and Robak, Tadeusz and Brown, Jennifer R and Kahl, Brad S and Ghia, Paolo and Giannopoulos, Krzysztof and Šimkovič, Martin and Österborg, Anders and Laurenti, Luca and Walker, Patricia A and Opat, Stephen S and Ciepluch, Hanna and Greil, Richard and Hanna, Merit and Tani, Monica and Trněný, Marek and Brander, Danielle and Flinn, Ian W and Grosicki, Sebastian and Verner, Emma and Tedeschi, Alessandra and de Guibert, Sophie and Tumyan, Gayane and Laribi, Kamel and García-Marco, José A and Li, Jian-Yong and Tian, Tian and Liu, Yu and Korolkiewicz, Roman and Szeto, Andy and Tam, Constantine S and Jurczak, Wojciech},
  title = {Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {7},
  pages = {780--787},
  doi = {10.1200/jco-24-02265}
}
Kostenlos starten →